A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer | Zendy

Lipton A. | Zendy; Harvey H. A. | Zendy; Santen R. J. | Zendy; Boucher A. | Zendy; White D. | Zendy; Bernath A. | Zendy; Dixon R. | Zendy; Richards G. | Zendy; Shafik A. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Author(s) -

Lipton A.,

Harvey H. A.,

Santen R. J.,

Boucher A.,

White D.,

Bernath A.,

Dixon R.,

Richards G.,

Shafik A.

Publication year - 1982

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/1097-0142(19821201)50:11<2265::aid-cncr2820501106>3.0.co;2-#

Subject(s) - aminoglutethimide , medicine , tamoxifen , randomized controlled trial , oncology , metastatic breast cancer , breast cancer , cancer , gynecology , aromatase

The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research